The UK’s medicines regulator has announced a recall of Xeal Pharma’s clopidogrel oral liquids after a formulation error left them containing less medicine than their labels state. The alert was issued on 26 October 2026 and covers all strengths of the company’s clopidogrel oral solution and oral suspension made before the notification.
If you take one of these liquids, contact your dispensing pharmacist or prescriber to check your supply and arrange a review. Do not stop clopidogrel, increase the amount you take or switch products yourself. The MHRA says to keep taking your medicine as advised until an alternative is arranged.
Which clopidogrel products are affected?
The MHRA recall, reference EL(26)A/43, names Xeal Pharma’s clopidogrel oral solution and oral suspension. This is a UK patient, pharmacy and wholesaler-level recall, not an announcement that every clopidogrel product has been recalled.
The notice applies to all strengths and to batches manufactured before it was issued. Its attached batch list gives the individual batch numbers, strengths, pack sizes, expiry dates and distribution dates. Ask your pharmacy to check the actual bottle and dispensing record against that list. Do not identify an affected medicine by its colour, bottle shape or an online illustration.
Clopidogrel tablets are not the products named in this particular recall. If you take tablets, this notice is not a reason to stop them. If you are unsure which formulation or manufacturer supplied your medicine, the dispensing pharmacy can help establish that before any treatment decision.
What went wrong with the liquid?
According to the MHRA, a formulation error means the affected batches contain 76% of the required amount of clopidogrel. Someone measuring the amount written on their prescription would therefore receive less active medicine than intended.
That finding does not provide a safe do-it-yourself dose correction. The prescribed treatment, the supplied formulation and any replacement need to be checked together by a healthcare professional. Do not try to compensate by taking extra liquid, adding tablets or adding aspirin.
The MHRA reports that no patient harm has been reported in relation to this issue. It also describes the manufacturer’s assessment that harm is not anticipated in people receiving the affected product for long-term prevention. These statements do not cancel the recall or show that every individual’s treatment is adequate; a review is still needed.
Why stopping clopidogrel can be dangerous
Clopidogrel is an antiplatelet medicine. It reduces the tendency of platelets, a type of blood cell, to stick together and form dangerous clots. It may be prescribed after a heart attack, stroke or mini-stroke, for peripheral arterial disease, or after a coronary stent procedure.
The NHS warns that stopping clopidogrel without medical advice can increase the risk of serious problems such as a heart attack or stroke. The recall therefore requires an organised replacement or treatment review, not an interruption chosen at home. This distinction matters for anyone taking it, including people who also have diabetes.
What to do with your bottle
- Contact the pharmacy that dispensed it. Have the bottle, carton, pharmacy label and batch number available if possible. Explain that you are asking about the Xeal Pharma clopidogrel liquid recall.
- Keep following your current instructions while seeking advice. The regulator says not to stop the medicine suddenly and to continue as advised until an alternative is obtained.
- Ask how the review and replacement will happen. Your pharmacist may need to contact your GP, specialist or other prescriber. Do not make your own changes while waiting.
- Return the affected product once a replacement is in place. Follow the pharmacy’s recall arrangements rather than discarding your supply first.
If your supply is running out before you can reach your usual team, seek prompt advice from an available pharmacist or urgent healthcare service. Do not leave the issue until you have no medicine remaining.
What pharmacies and prescribers have been asked to do
The MHRA instructs suppliers to stop supplying affected batches, quarantine remaining stock and return it through their supplier’s process. Pharmacies should identify and contact patients who received the batches. Where batch traceability is unavailable, the notice says to contact everyone dispensed the product from 20 July 2026.
That July date is a contact-tracing instruction for pharmacies, not a reason for a patient to assume a bottle is unaffected. Prescribers and clinicians involved in treatment or monitoring should also contact patients or carers to arrange review. The manufacturer says future stock will be made using the correct strength calculations; a pharmacist should confirm the suitability of any replacement supplied.
When symptoms need emergency help
A recall enquiry must not delay emergency care. Sudden facial drooping, arm weakness or speech difficulty can indicate a stroke. Call 999 in the UK immediately, including if the symptoms have stopped. Do not drive yourself.
Call 999 for tight or squeezing chest pain, chest pain spreading to an arm, neck or jaw, or severe difficulty breathing. Outside the UK, use the local emergency number. Do not wait for a pharmacy callback or try to establish whether a medicine fault caused the symptoms.
Common questions
Does this mean clopidogrel no longer works?
No. The notice concerns the amount of active ingredient in specified Xeal Pharma liquid products. It is not evidence that clopidogrel as a medicine has stopped being effective.
Can I use a different bottle or tablets instead?
Ask your pharmacist or prescriber to arrange the appropriate alternative. Different strengths and formulations are not interchangeable by guessing a volume or tablet amount.
Where can I find future medicine-safety updates?
Use the MHRA’s original notice for the batch list and product advice. Our Living Diabetes news section covers other relevant safety updates. Suspected adverse reactions can be reported through the MHRA Yellow Card scheme, but reporting is not a substitute for medical or emergency care.